ArticleScientific reports2025
Fagonia indica extract encapsulated in PLGA nanocarriers demonstrated enhanced therapeutic efficacy through improved intracellular uptake of photoactive metabolites.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fagonia indica (FI), a member of the Zygophyllaceae family, is known for its medicinally important components, such as glycosides, saponins, flavonoids, phenols, and alkaloids. The complex mixture of phytochemicals in the extract limits its aqueous solubility and bioavailability, resulting in low therapeutic outcomes. We aim to enhance the bioavailability of FI extract by encapsulating it into Poly (lactic-co-glycolic acid) (PLGA) nanoparticles (FI-PLGA NPs) and evaluate its cytotoxicity and phototoxicity against the BT-474 cell line. FI-PLGA NPs were prepared via a single emulsion solvent evaporation method. The optical properties, structural analysis, and hydrodynamic size of the synthesized NPs were characterised by UV-Visible spectroscopy, fluorescence spectroscopy, Fourier transform infrared (FTIR) spectrometry, X-ray diffraction (XRD) spectroscopy, and Dynamic light scattering (DLS). The measured particle size and zeta potential of FI-PLGA NPs were 217 nm and -30.5 mV, respectively. The in-vitro cytotoxicity and phototoxicity of FI extract and FI-PLGA NPs were measured using MTT assay. Results suggest that decreased cell viability is associated with higher intracellular concentration and fast drug internalisation when loaded on a nanocarrier compared to free extract. Moreover, a significant reduction in cell viability was observed after irradiation of light doses of 6 J/cm2 and 12 J/cm2. FI-PLGA NPs showed a higher cytotoxic effect against the BT-474 cell line than free FI extract, possibly due to prolonged and sustained drug release and faster cellular internalization of FI-PLGA NPs. Using a PLGA nanocarrier significantly improved the intracellular uptake of photoactive metabolites from the extract of Fagonia indica, enhancing the plant's therapeutic efficacy. The in-vivo anti-cancer potential of FI- PLGA NPs needs to be investigated to validate the effectiveness of these nano-formulations and open the door for their potential application in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.